The introduction of erythropoietin-stimulating agents (ESAs) in the 1980s represented a major therapeutic advance for renal anemia, significantly enhancing the quality of life in end-stage renal disease (ESRD) patients while reducing dependence on blood transfusions (Costa et al., 2008)
Dercums first patient was a woman with obesity with fat similar to a woman with Stage 3 lipedema (221)
When to seek medical advice: Persistent vomiting or diarrhoea lasting more than 2448 hours contact GP or NHS 111 Symptoms suggestive of hypokalaemia (weakness, cramps, palpitations) contact GP Difficulty maintaining adequate fluid intake or reduced urine output contact GP or NHS 111 Chest pain, severe palpitations, or fainting call 999 or attend A&E Any concerns about medication side effects Patients should report suspected side effects via the MHRA Yellow Card Scheme (yellowcard.mhra.gov.uk or via the Yellow Card app)
Modulation of the function of the multidrug resistance-linked ATP-binding cassette transporter ABCG2 by the cancer chemopreventive agent curcumin
Cycling: DSIP can be used continuously or cycled, depending on individual needs
Semaxen is manufactured by Everest Pharma Ltd